Nuformix (LON:NFX) Shares Down 2.6% – Should You Sell?
by Amy Steele · The Cerbat GemNuformix plc (LON:NFX – Get Free Report) shares traded down 2.6% during mid-day trading on Tuesday . The company traded as low as GBX 0.13 and last traded at GBX 0.15. 2,990,761 shares changed hands during mid-day trading, a decline of 90% from the average daily volume of 29,624,281 shares. The stock had previously closed at GBX 0.15.
Nuformix Stock Performance
The stock has a market capitalization of £3.86 million, a P/E ratio of -5.05 and a beta of 1.52. The firm has a 50-day moving average price of GBX 0.17 and a 200 day moving average price of GBX 0.19.
Nuformix (LON:NFX – Get Free Report) last released its earnings results on Thursday, May 28th. The company reported GBX (0.02) earnings per share for the quarter.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.